Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...
Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net ...
Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...
Researchers from the Mitochondrial Medicine Program at Children's Hospital of Philadelphia (CHOP) have better characterized a ...
Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders ...
A breakthrough new therapy has enabled mice to survive exposure to acute radiation, according to a new study that may lead to ...
National Stem Cell Bank Doubles Distribution to 133 in Last Year Stem cell availability surged last year, enhancing research ...
Zealand Pharma AS (ZLDPF) reports significant advancements in obesity treatments and a robust cash reserve, while navigating ...
The Germany Continuous Positive Airway Pressure (CPAP) market is set for steady growth, with projections indicating a rise from USD 313.2 million in 2025 to USD 441.8 million by 2035, reflecting a 3.5 ...
But there are non-infectious causes of infertility to consider as well.  In this episode, Dr. Fauna Smith, Assistant ...